BAGSVAERD, Denmark, Jan. 30, 2015 (GLOBE NEWSWIRE) --
Sales increased by 8% in local currencies and by 6% in Danish kroner to 88.8 billion.
- Sales of modern and new-generation insulin increased by 12% (10% in Danish kroner).
- Sales of Victoza® increased by 16% (15% in Danish kroner).
- Sales in North America increased by 11% (11% in Danish kroner).
- Sales in International Operations increased by 14% (4% in Danish kroner).
- Sales in Region China increased by 13% (13% in Danish kroner).
Gross margin improved by 0.5 percentage point in Danish kroner to 83.6% driven by a favourable price development and a positive impact from product mix.
Operating profit increased by 13% in local currencies and by 10% in Danish kroner to DKK 34.5 billion.
Net profit increased by 5% to DKK 26.5 billion. Diluted earnings per share increased by 8% to DKK 10.07.
The roll-out of Tresiba® continues. In Japan, Tresiba® has now captured 26% of the basal insulin market measured in monthly value market share since its launch in March 2013.
In December 2014, the US Food and Drug Administration (FDA) approved Saxenda® (liraglutide 3 mg), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity.
For 2015, sales growth is expected to be 6-9% and operating profit growth is expected at around 10%, both measured in local currencies. Reflecting the appreciation of key invoicing currencies and the related currency hedging effects, operating profit as reported is expected to grow by around 29%, whereas pre-tax profit is expected to grow approximately 16%.
At the Annual General Meeting on 19 March 2015, the Board of Directors will propose an 11% increase in dividend to DKK 5.00 per share of DKK 0.20. The Board of Directors has furthermore decided to initiate a new 12-months share repurchase programme of up to DKK 15 billion.
Lars Rebien Sørensen, president and CEO: "We are pleased with Novo Nordisk's financial performance in 2014; a more challenging year than usual. Levemir® and Victoza® drove most of our sales growth, and our new long-acting insulin Tresiba® continues to perform well. 2015 will be an important year for us with the first launches of Saxenda® and Xultophy® as well as significant results from our late-stage development portfolio."
|Mike Rulis||+45 3079 email@example.com|
|Ken Inchausti (US)||+1 609 514 firstname.lastname@example.org|
|Kasper Roseeuw Poulsen||+45 3079 email@example.com|
|Jannick Lindegaard Denholt||+45 3079 firstname.lastname@example.org|
|Daniel Bohsen||+45 3079 email@example.com|
|Melanie Raouzeos||+45 3075 firstname.lastname@example.org|
|Frank Daniel Mersebach (US)||+1 609 235 email@example.com|
Company announcement No 7 / 2015
Company announcement No 7 / 2015 http://hugin.info/2013/R/1890523/669362.pdf
Source:Novo Nordisk A/S